| Turkish population | Highest known prevalence, estimated at 1:10,000 to 1:20,000 due to a common MLC1 founder mutation |
| Japanese population | Relatively higher prevalence with multiple documented founder mutations |
| Palestinian population | Notable cluster of cases with specific HEPACAM mutations[@ikehara2023] |
| Agarwal community in India | Founder mutation identified in the MLC1 gene |
| Databases | OMIMOrphanetClinicalTrialsPubMed |